Currently available prognostic scoring systems in primary myelofibrosis (PMF) do not integrate clinical, histological, and molecular data, or they also required information on “other” mutations that are available in the clinical practice only in a very limited number of laboratories. In the present multicenter study, including 401 PMF patients, an integrated International Prognostic Scoring System (I-IPSS) was developed by combining IPSS, grade of bone marrow fibrosis (GBMF), and driver mutations molecular status (MS) to define PMF prognosis at diagnosis. Four prognostic categories were identified: I-IPSS–low risk (113 patients), I-IPSS–intermediate-1 risk (56 patients), I-IPSS–intermediate-2 risk (154 patients), and I-IPSS–high risk (78 patients). Median overall survival was 26.7 years in I-IPSS–intermediate-1, 10.8 in I-IPSS–intermediate-2, and 6.4 in I-IPSS-high-risk patients (log-rank test <0.0001); instead, it was not reached in the I-IPSS–low-risk cohort because of the extremely low number of registered deaths. The addition of GBMF and MS to IPSS improved the efficacy for predicting the risk of death. Indeed, the sensitivity of I-IPSS was significantly higher (P <.05) than that of IPSS, considering both total deaths and 5- and 10-year mortality. This comprehensive approach allows clinicians to evaluate mutual interactions between IPSS, GBMF, and MS and identify high-risk patients with poor prognosis who may benefit from aggressive treatments. More importantly, this integrated score can be easily applicable worldwide as it only required information that represent the good clinical practice in the management of PMF patients.

Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis : a practical approach / A. Iurlo, E.M. Elli, F. Palandri, D. Cattaneo, A. Bossi, I. Cortinovis, C. Bucelli, N. Orofino, F. Brioschi, G. Auteri, P. Bianchi, S. Fabris, G. Isimbaldi, E. Sabattini, L. Baldini, U. Gianelli. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - 37:4(2019 Oct), pp. 424-433.

Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis : a practical approach

D. Cattaneo;A. Bossi;I. Cortinovis;C. Bucelli;N. Orofino;S. Fabris;L. Baldini;U. Gianelli
Ultimo
2019

Abstract

Currently available prognostic scoring systems in primary myelofibrosis (PMF) do not integrate clinical, histological, and molecular data, or they also required information on “other” mutations that are available in the clinical practice only in a very limited number of laboratories. In the present multicenter study, including 401 PMF patients, an integrated International Prognostic Scoring System (I-IPSS) was developed by combining IPSS, grade of bone marrow fibrosis (GBMF), and driver mutations molecular status (MS) to define PMF prognosis at diagnosis. Four prognostic categories were identified: I-IPSS–low risk (113 patients), I-IPSS–intermediate-1 risk (56 patients), I-IPSS–intermediate-2 risk (154 patients), and I-IPSS–high risk (78 patients). Median overall survival was 26.7 years in I-IPSS–intermediate-1, 10.8 in I-IPSS–intermediate-2, and 6.4 in I-IPSS-high-risk patients (log-rank test <0.0001); instead, it was not reached in the I-IPSS–low-risk cohort because of the extremely low number of registered deaths. The addition of GBMF and MS to IPSS improved the efficacy for predicting the risk of death. Indeed, the sensitivity of I-IPSS was significantly higher (P <.05) than that of IPSS, considering both total deaths and 5- and 10-year mortality. This comprehensive approach allows clinicians to evaluate mutual interactions between IPSS, GBMF, and MS and identify high-risk patients with poor prognosis who may benefit from aggressive treatments. More importantly, this integrated score can be easily applicable worldwide as it only required information that represent the good clinical practice in the management of PMF patients.
bone marrow fibrosis; driver mutations; primary myelofibrosis; prognosis; risk categories
Settore MED/15 - Malattie del Sangue
Settore MED/08 - Anatomia Patologica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Iurlo_et_al-2019-Hematological_Oncology.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 776.05 kB
Formato Adobe PDF
776.05 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Iurlo_et_al-2019-Hematological_Oncology.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 3.26 MB
Formato Adobe PDF
3.26 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/677713
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact